Abstract
Hypereosinophilic syndromes (HES) are rare and heterogenous disorders characterized by persistent blood eosinophilia (absolute eosinophil count [AEC] >1500 cells/μL) and eosinophil-mediated end-organ involvement, including but not limited to dermatologic, pulmonary, gastrointestinal, and cardiovascular manifestations, impacting quality of life. Current treatment of symptomatic HES includes corticosteroids and corticosteroid-sparing agents. Patients often experience treatment-limiting or intolerable adverse effects despite available therapies and need additional therapeutic options.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
